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Abstract
Background: Oldenlandia affinis, commonly called ‘kalata-kalata’, a versatile plant used locally to treat malaria fever in some parts 
of  sub-Saharan Africa was investigated for anti-plasmodial and anti-inflammatory activities.
Objective: The study was designed to evaluate the antiplasmodial as well as anti-inflammatory activities of  whole extract and 
cyclotide-rich fraction of  Oldenlandia affinis
Method: The dichloromethane-methanol extract (ODE) of  the plant, O. affinis was investigated for suppressive and curative an-
tiplasmodial activities against Plasmodium berghei in mice. ODE and the cyclotide-rich fraction (CRF) was investigated for chronic 
and acute anti-inflammatory activities in rat models of  inflammation. Inhibition of  pro-inflammatory mediators was studied in 
RAW264.7 macrophages.
Results: ODE exhibited significant (p<0.05) reduction in mean parasitaemia in both the suppressive and curative models 
of  Plasmodium berghei infection in mice.Administration of  ODE(100, 200, or 400 mg/kg) and CRF (100, 200, or 400 mg/kg) 
produced significant inhibition of  rodent models of  acute and chronic inflammation . This observation is supported by the 
significant (P<0.05) inhibition of  pro-inflammatory mediators, inducible nitric oxide (iNO) and tumour necrosis factor-alpha 
(TNF-α), and the reactive radical scavenging activities in RAW264.7 macrophages.
Conclusion: These findings could explain, at least in part, the successes reported in the use of  the herb, Oldenlandia affinis in the 
traditional treatment of  malaria fever
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Malaria is a global scourge and remains a leading cause 
of  morbidity and mortality worldwide, especially in preg-
nant women and children, and particularly in tropical Af-
rica. Sub-Saharan Africa carries a disproportionately high 
share of  the global malaria burden. In 2015, the region 
was home to 88% of  malaria cases and 90% of  malar-
ia deaths1. Despite the remarkable progress made in the 
fight against malaria, drug therapies are becoming less 
and less effective, due to drug resistance by Plasmodium fal-
ciparum.2,3 Disappointed by apparent low effectiveness of  
orthodox anti-malarial treatments, and in search of  relief, 
people living in malaria endemic countries have often re-
sorted to the use traditional remedies either as a prophy-
lactic measure to prevent frequent malaria episodes or to 
cure themselves4. This makes the investigation of  these 
local remedies plausible and worth-while.  It has been 
reported that more than 50% of  new available drugs in 
the world today are still derived from natural sources.5 
An important role in the challenge is to discover new an-
ti-malarial drugs6.
Oldenlandia affinis (R. & S.) D.C. (Rubiaceae) is a scrambling 
perennial herb widespread in tropical Africa. During a Red 
Cross Relief  Mission in Democratic Republic of  Congo 
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in the 1960s, Dr. Lorents Gran, observed that women in 
that region used ‘kalata-kalata’, a medicinal tea made from 
the leaves of  the plant Oldenlandia affinis to induce labour 
and facilitate smooth and painless deliveries7. Later, in 
vivo studies in rats confirmed the uterotonic activity of  
O. affinis extract and the purified active ingredient, a pep-
tide, named ‘kalata B1’, after the traditional name for the 
native medicine, kalata-kalata. Twenty years later, further 
research elucidated a cyclic cystine knot motif  in its struc-
ture and identified the peptide as a cyclotide.8
In Benin Republic, Oldenlandia affinis is mixed with honey 
and used against learning impairment and the aqueous 
decoction used as anti-colic drink.9 Phytochemically, the 
plant has been shown to contain, apart from serotonin, 
several cyclotides with three cysteine-to-cystine bridges 
responsible for their special and compact structure, as 
well as their medicinal properties. Cyclotides, first isolat-
ed from Oldenlandia affinis, are small disulfide rich peptides 
isolated from plants.10 Typically containing 28-37 amino 
acids, they are characterized by their head-to-tail cyclised 
peptide backbone and the interlocking arrangement of  
their three disulfide bonds. These combined features 
have been termed the cyclic cystine knot (CCK) motif. 
To date, more than 100 cyclotides have been isolated and 
characterized; mostly from species of  Rubiaceae, Violaceae, 
and Cucurbitaceae families.
Cyclotides are responsible for most of  the therapeutic 
properties and potential of  O. affinis. Cyclotides have been 
reported to possess a broad range of  useful biological ac-
tivities, including anti-HIV11, insecticidal12, anti-cancer13, 
anti-fouling14, anti-microbial15, anti-viral activity16, hae-
molytic, neurotensin antagonism18, trypsin inhibitory19, 
and uterotonic activities11,14,20.
In some rural communities in South-Eastern Nigeria, the 
decoction of  O. affinis is used as anti-malarial and antife-
brile remedy. This practice motivated this study in which 
we investigated the anti-inflammatory and anti-plasmo-
dia activities of  the whole plant extract and cyclotide-rich 
fraction of  O.  affinis. The whole aqueous methanol extract 
of  O. affinis was investigated for preventive and curative 
anti-plamodial activities in mice infected with Plasmodium 
berghei. The effects of  the extract against acute and chron-
ic inflammatory responses were determined in rodent 
models and, in vitro, on the expression of  inducible nitric 
oxide, TNF-α and the scavenging of  reactive oxygen/ni-
trogen species (ROS/RNS) in cultures of  monocytic cell 
line (RAW264.7). 
Materials and methods
Collection of  plant material and preparation of  extract
The aerial parts of  Oldenlandia affinis were freshly collect-
ed in the month of  August, in Nsukka Local Government 
Area of  Enugu State, Nigeria. The collected plant mate-
rial was authenticated by a plant taxonomist, Mr. Alfred 
Ozioko of  International Centre for Ethnomedicine & 
Drug Development (InterCEDD) Nsukka, Enugu State-
where a voucher specimen (InterCEDD/994) has been 
deposited.  The plant material was washed in stream of  
clean water and contaminating debris removed, thereaf-
ter air-dried at room temperature, and then pulverised. A 
portion of  the powdered plant (700 g) was macerated in 
6 L of  a 1:1 water and methanol for 48 h with intermit-
tent agitations; the resultant mixture was filtered through 
Whatman (No. 1) filter paper and the filtrate concentrat-
ed in vacuo at 40°C using rotary evaporator. This whole 
aqueous-methanol extract of  O. affinis aerial parts (ODE) 
was as stored at -20 °C for future use.
The cyclotide-rich fraction was prepared using a previ-
ously reported protocol21.  Briefly, the whole aerial part 
extract (ODE) was enriched for cyclotide by partition-
ing repeatedly (3x) between an aqueous phase and equal 
volume of  dichloromethane in a separating funnel. The 
organic soluble fraction was discarded, and the aqueous 
layer, which contains the cyclotides as reported earlier22, 
was concentrated using a rotary evaporator. Freeze-dry-
ing of  the concentrated fraction yielded a dark-brown ex-
tract, a cyclotide-rich fraction (CRF), which was stored in 
aliquots at -20°C and used subsequently for the experi-
ments.
Preliminary phytochemical tests were carried out on both 
the aqueous-methanol extract and on the cyclotide-rich 
fraction using the procedures outlined by Harborne23.
Animals
Adult Swiss albino mice (18-25 g, 7-8 weeks old) of  both 
sexes were procured and housed in the Laboratory An-
imal Facility of  the Department of  Pharmacology and 
Toxicology, University of  Nigeria (Nsukka). The animals 
were housed under standard conditions 25 ± 2°C, rela-
tive humidity of  50 ± 5%, and a 12-h light/dark cycle,) 
and had access to standard rodent chow pellets (Live-
stock Feed PLC, Lagos, Nigeria) and unrestricted access 
to drinking water. All mice were allowed at least 5 days to 
acclimatize prior to use in the studies. The use and care 
of  the animals were in accordance with ethical guidelines 
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as contained in the European Union Directives for the 
Protection of  Animals used for Experimental and other 
Scientific Purposes (EU Directive: 2010/63/EU) of  2010 
which conforms with local institutional ethical guideline.
Median Lethal Dose (LD50) on ODE and CRF
The Median Lethal Dose (LD50) of  the ODE and CRF 
(of  ODE extract) was estimated in mice by the oral 
route using the method of  Lorke24. The tests involved 
two phases: the first involved determination of  the toxic 
range. The mice were placed in groups (n = 3) and ODE 
or CRF (10, 100, or 1000 mg/kg) was administered intra-
peritoneally (i.p). The treated mice were then monitored 
for 24 h for mortality. In the second phase, four different 
doses of  ODE or CRF were administered orally based 
on the earlier outcomes. The mice were observed for le-
thality and signs of  acute intoxication for 24 h. The LD50 
was then calculated as the geometric mean of  the highest 
non-lethal dose and the least toxic dose24.
Studies on anti-plasmodial effects of  ODE
Maintenance of  plasmodium parasites and parasite in-
oculation
Sample of  red blood cells parasitized by Plasmodium berghei 
was obtained from a donor-infected mouse maintained at 
Animal Facility Centre, Faculty of  Veterinary Medicine, 
University of  Nigeria Nsukka. Parasite was maintained 
by continuous re-infestation in mice. Parasitized mouse 
blood was diluted in sterile saline to obtain a 5x107 para-
sitized erythrocytes/ml.  Mice used in the study were in-
oculated intra-peritoneally with 0.2 ml of  infected blood 
suspension containing 107 P. berghei parasitized red blood 
cells using a 25G needle. Prior to inoculation of  recipient 
mouse, parasitemia in the donor mouse was ascertained 
by microscopic examination of  Giemsa-stained thin 
blood smear.
 
Evaluation of  Suppressive Anti-plasmodial activity 
of  ODE in infected Mice
Suppressive/prophylactic assay was used to evaluate the 
in vivo anti-malarial activity of  O. affinis whole aerial part 
extract (ODE) against P. berghei infection using the meth-
od described by Knight and Peters25. Twenty five Swiss 
albino mice of  either sex (18-25 kg) were infected by in-
traperitoneal inoculation of  107 P. berghei- parasitized red 
blood cells in 0.2 ml volumes. The mice were randomly 
assigned to five groups (n=5) and pre-treated(intraperi-
toneally, i.p.) with either normal saline (10 ml/kg/day) to 
serve as the negative control group, a standard anti-ma-
larial-artemether (100 mg/kg/day), or ODE (100, 200, or 
400 mg/kg/day). ODE and the controls were adminis-
tered from day zero through day 4. On day 5, thin blood 
smears were prepared from tail blood of  each mouse, 
fixed in absolute ethanol and stained with 10% Giemsa 
stain. The stained smears were examined microscopically 
(×100 magnification) and the number of  parasitized RBC 
counted in 10 different fields determined. Then the de-
gree of  parasitaemia (%) was calculated by:
  
 
The percentage inhibition of  parasitaemia was also calcu-
lated according to the formula:
Levels of  parasitaemia in the treated groups were then 
statistically compared to the negative control.
Evaluation of  curative anti-plasmodial activity of  
ODE on established plasmodium berghei infection in 
mice
To evaluate the curative anti-malarial properties of  
ODE on established Plasmodium berghei infection, twen-
ty five Swiss albino mice were each inoculated intraper-
itoneally with 1 × 107 P. berghei-parasitised RBCs in 0.2 
ml volumes on day zero26. Seventy-two hours later, the 
mice were assigned to five groups (n=5) and were treat-
ed once daily (i.p) (intra-peritoneally) with either 10 ml/
kg normal saline (negative control), artemether (100 mg/
kg; standard drug) and with three doses of  ODE 100, 
200, and 400 mg/kg) for 5 days. To determine the daily 
parasitaemia level, about three drops of  blood were col-
lected from the tail of  each mouse and smeared onto a 
microscope slide to make a thin film. The smears were 
fixed with absolute ethanol and stained with 10% Giem-
sa stain, and examined microscopically (×100 magnifica-
tion). The stained smears were examined microscopically 
(×100 magnification) and the number of  parasitized RBC 
counted in 10 different fields determined. Then the de-
gree of  parasitaemia (%) was calculated by:
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Effect of  ODE and CRF on carrageenan-induced 
acute paw inflammation in rats
The method described by Winter et al.27 was adopted. 
Twenty-five Swiss albino rats were randomly divided into 
5 groups (n=5). Each of  the animals in Group I received 
0.2 ml of  normal saline (intra-peritoneally) and served as 
the negative control group while animals in groups II were 
administered 50 mg/kg of  ODE; Group III received 100 
mg/kg of  ODE and Group IV received 200 mg/kg of  
ODE. Animals in Group V received piroxicam (50 mg/
kg; i.p) and served as the reference standard group. The 
groups are similar inseparate studies, but Group II-IV 
were administered CRF (50, 100 or 200 mg/kg; intraper-
itoneally) respectively. One hour after administration of  
drugs and extract, 0.1 ml of  sterile saline solution of  1% 
carrageenan was injected into the sub-plantar surface of  
the left hind paw. Paw size was studied by measuring the 
volume of  water displaced by the inflamed paw at time 0 
h (before carrageenan administration) and at time 0.5, 1, 
2, 4, 6 and 24 h after the carrageenan administration. The 
percentage inhibition of  paw volume in treated groups 
was compared with the negative control group.
The ability of  test agents to suppress paw inflammation 
was expressed as a percentage of  inhibition of  paw oede-
ma and calculated according to the following equation. 28
 Inhibition (%) = (C-T) / C   x 100
Where C = Mean increase in paw thickness of  control 
group and T = Mean increase in thickness of  treatment 
group.
Effect of  ODE and CRF on formaldehyde-induced 
_model of  chronic inflammation in rats
rat-model of  chronic inflammation was assessed utiliz-
ing formaldehyde-induced paw oedema29. Adult Swiss 
albino rats of  both sexes were grouped into five groups 
(n=5). Group I animals each received 0.2 ml of  normal 
saline (intraperitoneally) and served as the negative con-
trol group. Animals in groups II to IV received ODE 
(100, 200 & 400 mg/kg; i.p) or CRF (100, 200 & 400 mg/
kg; i.p) respectively. Animals in Group V received dexa-
methasone (1 mg/kg; intraperitoneally) and served as the 
reference standard group. One hour later, inflammation 
was induced by sub-plantar injection of  0.1 ml of  2% 
formaldehyde solution and repeated on day 3, while drug 
administration was continued from day 1 to day 10. Daily 
changes in oedema were evaluated by measuring the vol-
ume of  water displaced by the inflamed paw once daily 
for the 10 days.
The percentage inhibition of  paw volume in treated 
groups was compared to the negative control group. The 
ability of  test agents  to suppress paw inflammation was 
expressed as a percentage of  inhibition of  paw oedema 
and calculated according to the following equation 28.
Inhibition (%) = (C-T) / C   x 100
Where C = Mean increase in paw thickness of  control 
group and T = Mean increase in thickness of  treatment 
group.
In vitro experiments
Cell lines and culture conditions
RAW264.7 monocytic cell line was cultured in R-10 
(RPMI 1640 medium; Mediatech Inc., Manassas, VA) sup-
plemented with 10% heat-inactivated Foetal bovine saline 
(FBS), 50 µM 2-mercaptoethanol, 100 IU penicillin/ml, 
and 100 µg streptomycin/ml (Gibco, Grand Island, NY).
Effects of  CRF on cell viability
Effects of  CRF on RAW264.7 cell viability were evaluated 
using a modification of  the original MTT (3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) viability 
assay of  Mosmann 30. RAW 264.7 cells were cultured for 
24 h in 96-well flat-bottom plates at 5 × 104cells/well at 
37°C 5% CO2 chamber. Cells were then treated with grad-
ed concentrations of  CRF (5, 25, 50, 100, 250, or 1000 
μg/ml) or 1 μg lipopolysaccharide/ml (LPS; serotype 
0128:B12, L 4255; Sigma) as a standard mitogen. The cul-
ture plate was then incubated for 48 h at 37°C. At the end 
of  this period, 20 μl MTT (5 mg/ml in phosphate buff-
ered saline; PBS) was added to each well and the plates in-
cubated for 4 h at 37°C. The plates were then centrifuged 
and culture medium gently discarded. Formazan crystals 
formed in viable cells were dissolved by addition of  150 
μl DMSO/well and the optical density (OD) in each well 
African Health Sciences Vol 17 Issue 3, September, 2017 830
was then read at 570 nm in a Bio-Kinetic Reader-E312e® 
plate reader (Bio-Tech Instruments, Winooski, VT). The 
proliferation index (PI), reflecting cell viability, was calcu-
lated as Mean ODtest/Mean ODcontrol.
Effect of  CRF on LPS-evoked iNO production by 
RAW264.7
Nitric oxide production and release by RAW264.7 cells 
was measured indirectly by determining nitrite accumu-
lation in culture supernatant using the Griess reaction. 
RAW264.7 cells (1x105 cells/well) were seeded in 96-well 
flat bottom for 24 h. The cells were pre-treated for 2 h 
with CRF (0, 5, 25, 50, or 100 μg/ml) before LPS (1 mg/
ml) (serotype 0128: B 12, L 4255; Sigma, St Louis, MO) 
was added to the wells. After incubation, cell-free super-
natant was harvested and analysed. When analysis was 
not possible on the day of  collection, the supernatant was 
stored at -20 °C and analysed subsequently after thawing 
at room temperature.  In the assay for nitrite levels, 100 
ml of  cell-free culture supernatants were mixed with an 
equal volume of  freshly prepared Griess reagent in 96-
well plate and incubated at room temperature for 10 min. 
The absorbance was measured on a microplate reader at 
570nm (Bio-Kinetic Reader-E312e®; Bio-Tech Instru-
ments, Winooski, VT). Nitrite concentrations were ex-
trapolated from a standard NaNO2 curve included within 
each assay plate.
Effect of  CRF on LPS-evoked tumor necrosis factor 
(TNF)-α production/release by RAW264.7
The effect of  CRF on LPS-induced release of  TNF-α, 
a pro-inflammatory cytokine by macrophages was de-
termined. RAW264.7 cells 1x105 cells/well) were seed-
ed in 96-well flat bottom plate for 24 h. The cells were 
pre-treated for 2 h with CRF (0, 5, 25, 50, or 100 μg/ml) 
before LPS (1 mg/ml) was added to the wells. After incu-
bation, cell-free supernatant was harvested and analysed. 
When analysis was not possible on the day of  collection, 
the supernatant was stored at -20 °C and analysed subse-
quently after thawing at room temperature. The level of  
TNF-α in each supernatant was measured using a com-
mercial ELISA kit (Mouse TNF-α DuoSet®, R&D Sys-
tems, Minneapolis, MN) following manufacturer instruc-
tions. The concentration of  TNF-α was calculated from 
a standard curve of  the standard mouse TNF-α included 
ELISA assay. The level of  sensitivity of  the kit was 31.2 
pg TNF-α /ml.
Effect of  CRF on ROS and RNS by enhanced-lumi-
nol chemiluminescence
Chemiluminescence of  RAW264.7 macrophages was 
evaluated in Hank’s balanced salt solution (HBSS; pH 
7.4) by a modification of  the enhanced-luminol micro-
plate assay31,32. The principle of  the method is based on a 
luminol interaction with the phagocyte-derived ROS and 
RNS, which results in large measurable amounts of  light. 
30 RAW264.7 cells were seeded 2x105 cells/well into a 96-
well plate (white opaque- walled). The plate with treated 
with CRF (0, 5, 25, or 50 μg/ml) and incubated for 30 
min. Enhanced luminol solution (Pierce Biotechnology 
Inc., Rockford, IL) was added into the well and placed 
in a microplate luminometer (Synergy H1 Hybrid Multi-
Mode, BioTek Winooski, VT) and luminescence read for 
5 min. Thereafter, a solution of  phorbol 12-myristate 
13-acetate (PMA) was delivered automatically into each 
well to achieve a final concentration of  1 mM. Light emis-
sion expressed as relative light units (RLU) was recorded 
continuously at 37 °C for 60 min following PMA stimu-
lation. Intensity of  the chemiluminescence reaction was 
expressed as the integral of  the obtained kinetic curves 
which corresponded to the total amount of  light pro-
duced during the time of  measurements. Luminescence 
data was analysed and integrated using Gen 5 version 2.0 
(BioTek, Winooski, VT) and expressed as RLU.
Statistical analysis
All results were expressed as mean [± SEM]. Data were 
analyzed with Graphpad Prism™ (version 5.0) by a one-
way analysis of  variance (ANOVA) followed by a Bonfer-
roni’s post-hoc test. Differences between mean observa-
tions were considered significant at p-values ≤ 0.05.
Results
Phytochemical analysis and extractive yield
The yield of  the crude Oldenlandia affinis extract (ODE) 
was determined to be 204.7 g (5.12%, w/w), while that 
of  the cyclotide-rich fraction (CRF) was  41.5 g (5.93%, 
w/w). Preliminary phytochemical studies on ODE and 
CRF showed the presence of  a variety of  bioactive phy-
toconstituents in different amounts. Saponin, tannins, 
reducing sugar, glycosides, proteins, acidic compounds, 
alkaloids and flavonoid were found to be present in ODE 
while flavonoids, proteins and alkaloids were relatively 
more abundant in CRF; steroids and terpenoids were also 
present in CRF (Table 1).
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Table 1: Phytochemical analysis of extract and fraction 
Constituents Crude extract (ODE) Cyclotide-rich fraction (CRF) 
Flavonoids +++ +++ 
Glycosides - - 
Alkaloids +++ ++ 
Saponins - ++ 
Tannins + - 
Proteins +++ +++ 
Reducing sugars + ++ 
Steroids ++ + 
Terpenoids ++ - 
Fats & oils - - 
 
(Where - = absent; + = present in low amounts; ++ =   moderately present and +++ = abundantly present). 
Figure 1: Prophylactic effects ODE on Plasmodium berghei infection in mice. ***P<0.001, ns = not significant, compared to vehicle-
treated group (One-way ANOVA followed by Bonferroni’s post hoc test).
African Health Sciences Vol 17 Issue 3, September, 2017 832
Acute toxicity
Oral administration of  up to 5000 mg/kg of  both the 
extract ODE and its cyclotide rich fraction (CRF) to mice 
did not cause lethality in the two stages of  this test.  The 
LD50 of  both extract and fraction was therefore estimated 
to be greater than 5000 mg/kg24. Similarly, the animals 
did not exhibit signs of  acute intoxication during the pe-
riod of  observation.
Prophylactic Activities of  ODE on P. berghei Infection 
in Mice.
ODE exhibited significant (p<0.05) suppressive activity 
against Plasmodium berghei in vivo at all of  the three doses 
tested (Figure 1), seen as reduction in mean percentage 
parasitaemia on the 5th day post infection, compared to 
the untreated control group. Administration of  ODE 
(100, 200, and 400 mg/kg) reduced percentage parasi-
taemia from 72.0±5.7% to 63.5±7.5%, 22.2±7.7, and 
18.0±5.7 representing 11.8%, 69.1, and 75% reductions 
in parasitaemia, respectively, when compared to the un-
treated control group. Similarly, artemether (100 mg/kg) 
reduced parasitaemia to 4.2±1.7% (a 94.1% reduction 
versus control).
Curative activities of  ODE on P. berghei Infection in 
Mice.
ODE reduced the parasitaemia significantly (P<0.05) 
from the first day of  treatment and achieved the highest 
effect on the 5th day (Figure 2). At the dose of  100 mg/kg, 
administration of  ODE produced 6.5%, 17.5%, 33.6%, 
42.9%, and 56.2% reductions in parasitaemia from day 
1 to day 5 after treatment, respectively. For the group of  
mice that received 200 mg ODE/kg, the mean reductions 
in parasitaemia were in order of  0.0%, 18.43%, 34.56%, 
53%, and 60.8% from day 1 to day 5 after treatment, re-
spectively. Similarly, the mean percentage parasitaemia 
decreased in the groups that received 400 mg ODE/kg 
in the order 5.1%, 31.3%, 47.9%, 64.5%, and 78.3% from 
day 1 to day 5 after treatment, respectively (Figure 2). 
The group that was treated with the standard antimalarial 
drug, artemether (100 mg/kg) produced mean percent-
age parasitaemia reductions of  10.1%, 54.84%, 76.5%, 
88.5%, and 93.6% from day 1 to day 5 post treatment, re-
spectively, (Figure 2). When compared, the mean percent-
age parasitaemia suppression produced in the group of  
infected mice that received the standard drug, artemether, 
is not statistically different (P>0.05) from mean percent-
age suppression in the ODE (400 mg/kg) group.  The 
highest dose of  ODE (400 mg/kg) produced a maximum 
78.3% parasitaemia suppression on the 5th day while ar-
temether produced a  parasitaemia suppression of  93.6% 
on the 5th day.
Figure 2: Time-course effect of ODE on percentage parasitaeia of established Plasmodium berghei infection in mice. Data is presented 
as mean ± SEM. aP<0.001, bP<0.01 ; cP<0.05 compared to vehicle-treated group 
(two-way ANOVA followed by Bonferroni’s post hoc test).
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The effect of  the crude extract (ODE) on carrageen-
an-induced paw oedema in rats
On assessing the acute anti-inflammatory activity with 
this model, treatment with both the crude extract (ODE) 
and the standard agent, piroxicam, significantly reduced 
the paw oedema induced by carrageenan. In the negative 
control group, carrageenan produced a local paw oedema, 
reaching its maximum at 6 h (Table 2). Administration of  
the crude extract (ODE) at a dose of  100 mg/kg, pro-
duced the greatest significant inhibition of  78.26% at 6 
h (P<0.001) compared to negative control. The standard 
group (piroxicam 50 mg/kg) also produced significant re-
duction in paw oedema; exhibiting 100% inhibition at 2 h 
compared to the control (P<0.001).
Table 2: The effect of ODE on carrageenan-induced paw oedema in rats 
 
Treatment Paw volume (ml) 
0  h 0.5 h 1 h 2 h 4 h 6 h 
Negative 
control (normal saline) 
0.36±0.02 0.46±0.02 0.58±0.06 0.78±0.06 0.78±0.06 0.82±0.06 




































Values are presented as mean ± SEM. Percentage inhibition given in parenthesis. *P<0.05; **P<0.01; ***P<0.001 compared to negative control. 
The effect of  extract (ODE) on formaldehyde-in-
duced inflammation in rats
The anti-inflammatory effect of  the crude extract (ODE) 
in this formaldehyde-induced chronic arthritis model in 
rats is shown in the Table 3 below. Both crude extract 
and standard drug (Dexamethasone) significantly atten-
uated progression of  chronic inflammation induced by 
formaldehyde (P<0.05) compared to negative control. 
The greatest level of  inhibition was exhibited by ODE at 
400 mg/kg, producing a significant inhibition of  94.4% 
on Day 9 in this model. The standard group (Dexameth-
asone 1 mg/kg) also showed significant inhibition in oe-
dema exhibiting 77.6% inhibition (P<0.01) on Day 10.
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Chronic inflammation  index 
(measured as AUC of global 
oedema in cm-3. hr) 






Dexamethasone  1 269.28±18.48 31.29±4.72 
ODE 
100 357.12±28.56 8.88±7.29 
200 288.96±22.56 26.27±5.76 
400 280.32±10.8 28.48±2.76 
CRF 
100 279.12±26.88 28.78±6.86 
200 246.72±12.28 37.05±3.12 
400 279.84±16.80 28.60±4.29 
  
        Values are presented as mean ± SEM. Percentage inhibition given in parenthesis.  
        *P<0.05; **P<0.01; ***P<0.001 compared to negativecontrol 
Effect of  crf  on viability of  raw264.7 cells
Treatment of  RAW264.7 with 5-1000 µg CRF/ml for 48 
h showed that the cells remain largely viable at concen-
tration less equal to or 250 µg/ml (Figure 3). The via-
bility of  the RAW264.7 cells was as high as 96.87% at 
100 µg CRF/ml. However, cell viability was reduced to 
85.43% and 76.54% following exposure to 500 and 1000 
µg CRF/ml, respectively.
Figure 3: Effect of CRF on viability of RAW264.7 cells
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Effect of  CRF on LPS-induced nitric oxide produc-
tion in RAW264.7 culture
The effect of  the CRF on the release of  nitrite from 
LPS-induced RAW264.7 cells is shown in Figure 4.
LPS-stimulated iNO expression was inhibited in a con-
centration-related manner when the RAW264.7 cells 
were treated with CRF (5-100 μg/ml). Pre-treatment of  
RAW264.7 cells with graded doses of  CRF significantly 
(P<0.05) inhibited LPS-induced iNO levels in the culture 
supernatant in a concentration-related manner. Stimula-
tion of  RAW264.7 cells with LPS (1 μg/ml) evoked a lev-
el of  iNO up to 41.12[±0.82] μM compared to the iNO 
level of  5.64[±0.19] μM measured in the supernatant of  
unstimulated culture. However, pretreatment with CRF 
(5, 10, 25, 50 and100 μg/ml) significantly (P<0.05) inhib-
ited the production of  inducible nitric oxide from mean 
level of  41.12[±0.82] μM in culture wells treated with 
LPS alone to 30.9[±1.10], 27.76[±0.23], 24.54[±0.83], 
15.49[±0.75] and  12.47[±0.43] μM; representing an in-
hibition of  28.81 [±3.11], 37.66[±0.65], 46.73[±2.33], 
72.24[±2.12] and 80.75[±1.21] %, respectively. The 
iNO median inhibitory concentration (IC50) of  CRF in 
RAW264.7 is estimated as 49.53 μg/ml.







Effect of  CRF on LPS-evoked TNF-α production in 
RAW264.7 culture
The effect of  the CRF on the production of  a proinflam-
matory cytokine, TNF-α from LPS-induced RAW264.7 
cells is shown in Figure 5.
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LPS-evoked release of  TNF-α was inhibited in a con-
centration-dependent manner when the RAW264.7 cells 
were treated with CRF (5-100 μg/ml). Pre-treatment of  
RAW264.7 cells with graded doses of  CRF significantly 
(P<0.05) inhibited LPS-induced iNO levels in the culture 
supernatant in a concentration-related manner. Stimula-
tion of  RAW264.7 cells with LPS (1 μg/ml) induced a 
high level of  TNF-α of  1093.00[±63.6] pg/ml compared 
to the TNF-α level of  34.75[±3.20] pg/ml measured in 
the supernatant of  unstimulated culture. However, pre-
treatment with CRF (5, 10, 25, 50 and100 μg/ml) signifi-
cantly (P<0.05) diminished the TNF-α production from 
the mean value of  1093.00[±63.6] pg/ml in LPS treated 
wells to 916.70[±17.64], 593.30[±29.63], 470.00[±15.28], 
393.30[±29.63], and 260.00[±8.66] pg/ml; representing 
an inhibition of  16.66[±1.67], 47.22[±2.80], 58.87[±1.44], 
66.12[±2.80] and 78.71[±0.82] %, respectively. The 
TNF-α median inhibitory concentration (IC50) of  CRF in 
RAW264.7 is estimated as 50.17 μg/ml.
Inhibition of  ROS and RNS induced in PMA-stimu-
lated RAW264.7 cells by CRF
Changes in production of  ROS/RNS were determined 
by enhanced-luminol chemiluminescence assay. Pre-treat-
ment of  RAW264.7 macrophages with CRF (5, 10, 25, 
50 and100 μg/ml) followed by stimulation with PMA (1 
mM) caused significant (P<0.05) and concentration-de-
pendent suppression of  chemiluminescence detected and 
recorded over a 60 min period by a microplate luminom-
eter (Figure 6). At 50 and 100 μg/ml, the chemilumines-
cence of  luminol evoked by ROS/RNS was inhibited by 
as much as 72.24 [±2.12] and 80.75 [±1.21] %, respec-
tively by CRF.
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Figure 6: Inhibition of reactive oxygen species (ROS) and reactive nitrogen species (RNS) induced in 
PMA-stimulated RAW264.7 cells by CRF
Figure 6: Inhibition of reactive oxygen species (ROS) and reactive nitrogen species (RNS) induced in 
PMA-stimulated RAW264.7 cells by CRF
Oldenlandia affinis, a herb with versatile application in tra-
ditional folklore medicine. The local use of  herbal teas 
and decoctions of  O. affinis for the treatment of  malar-
ia, malaria fever and other diseases  which are associated 
with inflammation inspired this study in which the pro-
phylactic and curative anti-plasmodial activities, as well as 
anti-inflammatory and reactive radical scavenging prop-
erties of  cyclotide-rich extract and fraction of  Oldenlandia 
affinis were studied.
Oldenlandia affinis belongs to the Rubiaceae family of  me-
dicinal plants. Previous studies have shown that O. affin-
is is rich in cyclotides. Cyclotides belong to a family of  
special proteins characterized by their head-to-tail cy-
clic backbone and a cystine knot arrangement of  three 
conserved disulfide bonds.39 They are remarkably stable 
and are characterized by a variety of  bioactivities. It is 
believed that their natural presence is to serve as a de-
fensive mechanism, protecting the plants in which they 
are found from pest or pathogens.10 The circular protein 
backbone together with the knotted arrangement of  di-
sulfide bonds is unique structural motif  and confers cy-
clotides exceptionally stability to heat and resistance to 
proteolysis.40 The stability of  cyclotides make them very 
attractive scaffold for drug development and other phar-
maceutical applications.
Discussion
The centrepiece in the global treatment and control of  
malaria for over a decade has been the Chinese herb, 
Artemisia annua-derived artemisinin and the artemisi-
nin-based combination therapy (ACT). The ACT is rec-
ommended by the World Health Organization as first-
line treatment of  uncomplicated Plasmodium falciparum 
malaria in sub-Saharan Africa.33 The combination com-
prises a fast-acting artemisinin derivative with rapid effect 
on parasite clearance, and a long-acting drug to prevent 
recrudescence and development of  resistance. Despite 
huge success recorded with the use of  ACT, there are in-
creasing case reports of  failure and resistance.34-38 The in-
creasing cases of  failures and resistance to ACT is a major 
motivation and incentive for increased research efforts 
aimed at getting a potent and cost-effective alternative 
treatment against the menace of  Plasmodium falciparum.
Historically, many successful anti-malarial treatments 
such as quinine and artemisinin have been derived from 
medicinal plants. This research is partly motivated by the 
belief  that it is still possible to obtain successful antima-
larial molecules or lead molecules from medicinal plants, 
especially from herbs used by locals in the treatment of  
malaria and malaria fever. This present research was de-
signed to evaluate cyclotide-rich extract and fraction from 
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In the prophylactic anti-plasmodial assay, prior treatment 
with the extract of O. affinis, ODE significantly reduced 
parasitaemia following Plasmodium berghei infection. The 4 
day suppressive test is a standard test commonly used for 
anti-malarial screening.41  The extract produced signifi-
cant dose related parasitaemia suppression in all the treat-
ed groups with parasitaemia suppression as high as 69.1% 
and 75% observed in the groups treated with 200 mg and 
400 mg ODE extract/kg. The extract also showed signif-
icant dose related reduction in parasitaemia in established 
(curative) Plasmodium berghei infection, slightly lower than 
the effect of  artemether, which in this study was used as 
standard control drug.
The results of  the anti-plasmodial tests showed that the 
extract is active against the P. berghei malaria parasite used 
in this study and is consistent with the ethnomedicinal 
use of  Oldenlandia  affinis herbal decoctions and tea in the 
traditional treatment of  malaria and malaria-related fever 
in south eastern Nigeria. Plasmodium berghei rodent mod-
el of  plasmodial infection has been shown to produce 
disease features that are similar to those of  human ma-
laria infection.42-44  In this model, substances that reduce 
parasite multiplication (anti-plasmodial effect) in the host 
were considered to possess anti-malarial activity.45
In this study, preliminary phytochemical analysis showed 
that apart from cyclotides protein, the methylene chlo-
ride/methanol extract O. affinis (ODE) showed positive 
reactions for the presence of  flavonoids, alkaloids and 
proteins, tannins, steroids and terpenoids. Flavonoids, al-
kaloids and proteins are most abundant constituents in 
ODE. Cyclotide-rich fraction (CRF) was found to con-
tain flavonoids, alkaloids, saponins, proteins and steroids. 
Flavonoids and proteins were the most abundant constit-
uents. In the acute toxicity studies in mice, the LD50 of  
both ODE and CRF was estimated to be greater than 5 
g/kg. This signifies that at such high doses, these extract 
and fraction of  O. affinis did not cause lethality nor pro-
duced signs of  intoxication in the tests mice. A remote 
risk for possible acute intoxication is implied and thus 
they could be considered reasonably safe for all practical 
purposes.24
Malaria causes an acute systemic human disease that 
bears many similarities, both clinically and mechanisti-
cally, to those caused by other microbial (bacteria, rick-
ettsia, and viruses) infections.46 Several researchers have 
shown or argued that most of  the pathology seen in ma-
laria infection, as well as  other infectious diseases could 
be explained by activation of  the inflammatory system, 
with the balance between the pro- and anti-inflammatory 
cytokines tipped in favour of  the onset of  systemic in-
flammation.47-49
From the foregoing and on the strength of  the traditional 
use of  the herb in the treatment of  malaria and malar-
ia-related fever, it was necessary to investigate the extract 
and CRF for activities against acute and chronic inflam-
mation in rats models as well as free radical scavenging 
potentials. In the study, group of  rats administered both 
the extract and fraction of  O. affinis showed remarkable 
anti-inflammatory potentials. Treatment with ODE and 
CRFsignificantly reduced carrageenan-induced paw oe-
dema in rats compared to the untreated control. Carra-
geenan, a potent phlogistic agent, produces inflammation 
through the release of  several inflammatory mediators. 
These chemical mediators produce increase in vascular 
permeability thus prompting fluid accumulation in tis-
sues, which result in oedema.50,51 Hence, reduction in paw 
oedema may be due to inhibition of  these inflammatory 
mediators by the treatment with ODE and CRF. The in-
hibition produced by these agents is slightly lower than-
the effect of  the reference standard drug, piroxicam.
Similarly, the administration of  ODE and CRF signifi-
cantly attenuated progression of  inflammation induced 
by formaldehyde in rat models compared to negative 
control. This effect was observed to be dose-dependent 
with the highest dose inhibition of  chronic inflammation 
occurring at 400 mg ODE/kg. The cyclotide-rich frac-
tion (CRF) also exhibited a similar effect as evidenced 
by its significant attenuation of  the progression of  oede-
ma induced by formaldehyde in rat model of  chronic in-
flammation at an extent slightly lower than the inhibition 
produced by the standard treatment of  1 mg dexameth-
asone/kg. Inhibition of  formalin-induced pedal oedema 
in rats used as experimental chronic inflammation model 
is considered a suitable and reliable model to screen puta-
tive drug substances for chronic anti-inflammatory activ-
ity, as it closely resembles human arthritis.52
In a similar manner, in vitro anti-inflammatory assays 
showed that CRF inhibited lipopolysaccharide-induced 
released of  pro-inflammatory mediators in cultures of  
RAW267.4 monocytic cells in a concentration-dependent 
manner. Inducible nitric oxide as well and TNF-α evoked 
by pretreatment of  the macrophage cells were signifi-
cantly (P<0.05) inhibited by treatment of  5-100 μg CRF/
ml. These inhibitions are not likely due to cytotoxicity 
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as the viability of  the cells was observed to be greater 
than 96.87% at the concentrations of  CRF used in the 
assay. There is now remarkably widespread acceptance 
that cytokines such as tumour necrosis factor (TNF) and 
interleukin-1 (IL-1) are the essential mechanism of  sys-
temic disease caused by infectious agents.53,54 High levels 
of  these pro-inflammatory cytokines explain some of  the 
notable symptoms of  malaria disease such as anorexia, 
tiredness, aching joints and muscles, fever and sleepiness 
that patients experience in both Plasmodium vivax and Plas-
modium falciparum malaria.55-57
The TNF-α and iNO oxide play a prominent role in host 
defence against variety of  infections, including plasmodia 
infection. Excess production of  iNO is associated with 
several diseases, including arthritis, autoimmune diseas-
es, and septic shock and in several other chronic inflam-
matory diseases. The iNO is known to contribute to the 
inflammatory cascade by increasing vascular permeability 
and extravasations of  fluids and proteins at inflammato-
ry sites.58,59 Inhibition of  high-output of  NO production 
is thus a therapeutic strategy currently advocated for in 
the treatment of  various inflammatory diseases. This 
study has demonstrated that the CRF is a potent inhib-
itor of  TNF-a and iNO production in LPS-stimulated 
RAW264.7 macrophages.
In a recent contribution on the use of  traditional herbal 
medicine in the treatment of  malaria, it has been noted 
that inflammation is an important mechanism underlying 
the pathology of  malaria and that most traditional ther-
apy used by locals to treat malaria-related fever possess 
anti-inflammatory action.60
Treatment with CRF produced a significantly (P<0.05) 
lower level of  reactive oxygen and reactive nitrogen spe-
cies (ROS and RNS) in culture of  RAW246.7 macrophages 
activated by PMA. Chemiluminescence of  enhanced-lu-
minol was used as an indicator for the production of  
ROS/RNS in macrophages activated by PMA as a stimu-
lant of  protein kinase C.31,32,61   The close associations be-
tween ROS and RNS and chronic inflammation are well 
documented. ROS induces chronic inflammation by the 
induction of  COX-2, inflammatory cytokines (TNF-a, in-
terleukin-1 (IL-1), IL-6), chemokines (IL-8, CXCR4) and 
pro-inflammatory transcription factors (NF-κB). [62-64]
One of  the many actions of  the cytokines responsible for 
systemic inflammation is to disable oxidative phosphor-
ylation within mitochondria. There is also a widely held 
consensus that infection with falciparum malaria is often 
fatal because mitochondria are unable to generate enough 
ATP to maintain normal cellular function.65,66  It is be-
lieved that apart from the sequestration of  parasitized red 
cells that prevents sufficient oxygen getting to where it is 
needed, an equally important way ATP deficiency arises 
in malaria is an inability of  mitochondria, through the ef-
fects of  inflammatory cytokines on their function, to uti-
lise available oxygen67,68 The reduced capacity of  oxidative 
phosphorylation and concomitant ATP generation driven 
by pro-inflammatory cytokines released in malaria infec-
tion, as well as in other infectious diseases, explains the 
lethargy and tiredness associated with malaria infection.69
Apart from the beneficial anti-plasmodial activities re-
corded, the reactive radical(ROS/RNS)-scavenging ac-
tivity and the anti-inflammatory activities of  ODE and 
CRF are equally beneficial.  These properties are relevant 
in the overall management and treatment of  malaria and 
malaria fever. Complete isolation and characterization of  
the cyclotide was not achieved in the present study. A fur-
ther study in which the cyclotides in Odenlandia affinis are 
isolated and completely characterized will be necessary 
in harnessing this unique and versatile cyclic protein as 
therapeutic option in a wide variety of  ailments.
Conclusion 
This study showed that the dichloromethane/methanol 
extract and the cyclotide-rich fraction of  the plant, Old-
enlandia affinis showed anti-plasmodial activity against 
Plasmodium berghei using prophylactic and curative models 
in infected mice. Treatment with these extract and frac-
tion also showed potent  activities in acute and chronic rat 
models of  inflammation which could be explained by the 
inhibition of  expression and release of  pro-inflammatory 
mediators (iNO and TNF-α) and reactive radical (ROS/
RNS) scavenging activities witnessed in culture of  mac-
rophages in vitro. These findings could explain, at least 
in part, the successful use of  the extract and decoctions 
from Oldenlandia affinis in the traditional treatment of  ma-
laria and malaria-associated fever.
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